Patients with relapsed low-grade follicular lymphomas (LGFL) frequently respond to subsequent therapy and can have long survival, but are rarely cured. Factors associated with complete remission (CR) rate, length of survival, and time to treatment failure (TTF) after relapse are not well known. We assessed such factors by multivariate analysis in a retrospective review of 95 patients with relapsed LGFL treated with investigational chemotherapy regimens at our institution. The CR rate after therapy was 22%; the likelihood of achieving CR was inversely associated with the number of previous treatment failures (P < 0.001) and serum LDH level (P < 0.05). Both the presence of constitutional symptoms and a history of more than two previous treatment failures were associated with shortened survival and TTF. Hemoglobin level was also significantly associated with survival. Prognostic models for survival and TTF were derived to define patient groups with different projected outcomes after therapy for relapsed disease. The results of this study can be used to select patients for new investigational treatments and to evaluate the outcome of such therapies.
Introduction
Low-grade follicular lymphomas (LGFL) are defined as: a) follicular small cleaved cell lymphoma and; b) follicular mixed small cleaved cell and large cell lymphoma [1] . Although patients with these lymphomas typically have advanced disease at presentation, median survival ranges from 5 to 9 years [1] [2] [3] [4] . Initial treatments have included either single alkylating agents or combination chemotherapy with or without radiation therapy; complete response rates range from 54% to 88% [5] [6] [7] [8] [9] . The advanced stages of these disorders manifest a pattern of continuous relapses, and the cure rate is very low [3] [4] [5] [6] ; most patients eventually die of lymphoma or the complications of its treatment [3, 10, 11] . Once relapse occurs, many treatment approaches have been attempted, including combination chemotherapy and biological response modifiers [12] [13] [14] . Unfortunately, none has cured a significant number of patients. Comparisons of the efficacy of diverse therapies are difficult due to the lack of prognostic factors of outcome.
We have developed several investigational regimens for the treatment of patients with relapsed lymphoma. In an attempt to define factors associated with complete remission rate, survival, and time to treatment failure (TTF) in this population, we retrospectively reviewed records of 95 consecutive patients with relapsed LGFL treated between 1980 and 1986 in the M.D. Anderson Cancer Center. Follow-up was at minimum 5 years due to the long natural history of these disorders. We report prognostic factors found for these patients and present models for separating patients into distinct risk groups. The models can be used for design and interpretation of clinical trials of new therapies.
Patients and methods

Patient characteristics
Ninety-five consecutive patients with relapsed LGFL were treated with investigational chemotherapy regimens at the M.D. Anderson Cancer Center between January 1980 and September 1986. Patients were eligible if they had progressive or relapsing disease after chemotherapy. Centralized Pathology review was mandatory. Additional tissue biopsies were obtained at the time of relapse, whenever possible, to rule out transformation. Patients with transformation to a higher histologic grade of lymphoma prior to accrual were not included in this analysis. Sixty patients had achieved a CR to prior treatment, 27 had achieved partial remissions (PR), and 8 had never achieved objective responses to prior treatments. All but 5 patients had received doxorubicin-containing regimens. The median overall survival after diagnosis was 84 months (range . The median duration of first response was 24 months (range 1-160). Only four patients were treated initially with radiotherapy (two stage I, one stage II, and one stage III), and all subsequently failed chemotherapy (which included doxorubicin in three) prior to our treatment. These patients had a median duration of first remission of 6 years, and a median number of 4 prior treatment failures. See Table 1 for other patient characteristics. 
Treatment regimens
All patients were treated in protocols active against non-Hodgkin's lymphoma (Table 2 ) [12, [15] [16] [17] [18] [19] [20] . If more than one such regimen was given, only the first one was analyzed. To assure full availability of data and consistent evaluation of response, we only analyzed the patients' clinical course from the time of investigational treatment at M.D. Anderson. Three protocols were based on the combination of ifosfamide and etoposide to which amsacrine (AIVP-16) |16), methotrexate (IMVP-16) |17) or methyl-GAG and methotrexate (MIME) (18| were added. DHAP combined dexamethasone, highdose ara-C, and cis-platinum |19|, and CMED contained cyclophosphamide, methotrexate, etoposide, and dexamethasone [20] . In the single-drug regimens, bisantrene 300-500 mg/m 2 intravenously (IV) was given every 3 weeks [15] , and fludarabine 25 mg/m 2 FV daily x 5 was administered every 4 weeks [16|. All patients gave informed consent. Initial evaluation included history and physical examination, blood counts, SMA-12, electrolytes, urinalysis, bone marrow aspiration and biopsy, chest X-ray, and CAT scan of the abdomen and pelvis and/or lymphangjogram. Response was evaluated by repeating all previously abnormal tests.
Definitions
Prior treatment failure: relapse or progression following a chemotherapy regimen, or following adequate front line radiotherapy for nodal disease. CR: disappearance of all evidence of disease and symptoms related to lymphoma for >\ month. PR: >50% reduction in the sum of the products of the perpendicular diameters of measurable lesions for > 1 month. All other outcomes were considered failures.
Prognostic factors
Multiple variables were evaluated to determine their relationship with response, survival and TTF after therapy. Parameters were recorded both at the time of front line therapy (histologic subtype, sex, age, stage, number of extranodal sites, and constitutional symptoms), and at the time of treatment (response to initial therapy, prior use of doxorubicin, duration of first response, stage, treatment regi- [20] DHAP[19| Fludarabine [16] Total Number (CR) 9(1) 6(1) 34 (5) 8 (3) 18 (6) 9 (2) 11 (3) 95 ( men, number of extranodal sites, LDH level, hemoglobin level, platelet count, constitutional symptoms, number of prior treatment failures, and involvement of bone marrow, spleen or mediastinum). The Ann Arbor criteria were used for staging.
Statistical methods
Survival was calculated from initiation of therapy to the date of last follow-up or death. TTF was measured from the initiation of therapy to relapse, progression, or death from any cause [21) . The method of Kaplan and Meier was used to plot curves for survival and TTF [22] . All times are expressed as median, followed by 95% confidence intervals. All P-values are two-sided. Differences in response rates between prognostic subgroups were assessed by the chi-square test (without continuity factor). Survival and TTF times in distinct patient groups were compared using the logrank test [23] . In univariate analysis, several different cut-off points were examined for observations with multiple values to identify that which produced the best separation of survival of TTF curves. Consequently, cut-off values could differ for the same variable (e.g., LDH) when analyzed for CR^ survival, or TTF. The selected cut-off points were used in the multivariate analysis performed according to the Cox proportional hazards model |24|. Variables used in the multivariate analyses were those associated with univariate P-values <0.05. Multivariate analyses were stratified by regimen (AIVP-16, IMVP-16, or MIME versus all other treatments; see details below) to eliminate treatment as a source of variation in outcomes.
Results
Seventy-seven patients had died, and 18 were alive as of June 1991. The median follow-up from therapy for surviving patients was 83 months (range 63-119). The overall objective response rate was 49%, with a CR rate of 22%. The median survival after treatment was 20 months (14-38) (Fig 1) . The median TTF after treat- LDH <350 >350
• Chi-square test. ment was 4 months (3-6) (Fig. 2) ; patients achieving CR had a median TTF of 22 months (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . Two patients were continuously disease free at 82+ and 97+ months; these patients were treated respectively with bisantrene and MIME. Table 4 shows factors identified through univariate analysis as significantly associated with decreased survival. As previously described [12] , therapy with the ifosfamide/etoposide regimens (ATVP-16, IMVP-16, and MIME) was associated with shorter survival than the other regimens, as well as resulting in lower CR rates in this patient group. Due to the concern that prognostic factors could vary depending on the effectiveness of treatment, we stratified the patients in two groups: stratum A included patients treated with ifosfamide/etoposide combinations (median survival 14 months (10-27)) and stratum B included patients treated in all other regimens (median survival 38 months (18-54)). The first step in multivariate analysis was a forward stepwise selection among significant characteristics by univariate analysis. The variables that were selected, in order, were constitutional symptoms, number of extranodal sites, hemoglobin (all at the time of treatment), and number of prior failures. Survival among the 16 patients with constitutional symptoms was so poor that no attempt was made to identify other factors within that subset, and other prognostic factors were analyzed only among the remaining 79 patients. Significant variables in this group included number of prior failures (P -0.005), hemoglobin (P -0.012), and number of extranodal sites (P = 0.046). The three variables determine eight subsets of patients (nine counting the one for patients with symptoms). To see whether some of these could be combined, we first examined plots of survival according to number of prior failures and hemoglobin, separately for the two treatment groups. Patients with more than two prior failures and hemoglobin <12 g/dL did worse than other patients, but there were no consistent differences among the other subsets. Furthermore, survival curves for these unfavorable patients were very similar to those for patients with constitutional symptoms. The unfavorable subset was thus defined as those patients with symptoms or those with both >2 prior failures and hemoglobin <12 g/dl (number = 32); all other patients (number -63) constituted the favorable subset (Fig 3) . Number of extranodal sites did not improve categorization of patients and was not included in the prognostic model. Median survival for the unfavorable subset was 4 months (2-6) for stratum A and 5 months (3-18) for stratum B; in the favorable subset, the median survival for stratum A was 27 months (14-44), and 48 months (37-not reached) for stratum B.
Prognostic factors for complete response after treatment
Prognostic factors for survival after treatment
Prognostic factors for TTF
Univariate analysis showed significant correlations for several factors at the time of treatment (Table 5) . Again, therapy with the ifosfamide/etoposide regimens (ATVP-16, IMVP-16, and MIME) was associated with poorer prognosis than with the other regimens (median TTF with 95% CI, 4 months (3-6) vs 8 months (4-11), P -0.092), thus justifying stratification by treatment group. In the multivariate analysis, the characteristic most strongly associated with TTF was constitutional symptoms at the time of treatment (P -0.003), followed by number of prior treatment failures (P •= 0.004). Restricting attention to the 79 patients without symptoms, number of prior failures was the only characteristic significantly associated with TTF (P < 0.001).
Examination of TTF curves indicated that patients with symptoms and those without symptoms but with >2 failures (number -45) have clearly unfavorable prognosis, whereas patients without symptoms and with <2 prior failures (number -50) have a favorable prognosis (Fig 4) . The respective median TTF for the favorable prognosis patients in strata A and B were 9 months (4-12) and 13 months (5-24); for the unfavorable prognosis patients, the values were 2 (2-4) and 4 (2-8) months.
Transformation
The disease underwent transformation to a higher histologic grade in 17 patients after therapy; this event was detected at autopsy in 2 patients and from biopsies in the remaining 15. The median survival after transformation was poor (6 months; 95% CI, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . We were unable to identify factors present at the time of diagnosis or at the time of treatment that were predictive of subsequent transformation.
Discussion
We previously investigated the factors associated with CR in patients with relapsed lymphoma [12] , in a study that included patients with all histologic grades. However, a separate analysis for the low-grade lymphomas was not performed. Our analysis of 95 such patients shows that CR was more likely in patients with fewer than three previous treatment failures and with lower LDH levels. These findings are potentially valuable for investigators designing and evaluating new regimens. Patient with unfavorable characteristics could be either excluded or stratified separately in such studies. This patient population was treated with several chemotherapy regimens of diverse efficacy. We have considerable experience with combinations based on ifosfamide and etoposide for the treatment of relapsed lymphomas [12, 17, 18, 20] . Multivariate analysis showed these regimens to produce worse results in the low-grade follicular lymphomas. This observation confirms preliminary reports [12] of different activity by histological subtype, and suggests that other regimens should be employed for these histologies. The limited data available with the single drugs bisantrene and fludarabine are encouraging, and these two drugs deserve further investigation as part of combination chemotherapy regimens in these diseases.
Patients with low-grade follicular lymphomas have a long overall survival, in spite of the fact that their disease usually is diagnosed at an advanced stage [1, 2, 4, 8] . Survival can still be prolonged after relapse occurs, but predictive factors for survival and TTF after relapse have not been previously identified. By multivariate analysis, two independent variables were strongly predictive of duration of survival and TTF after therapy. Constitutional symptoms, previously described as unfavorable in front line treatment [2, 3, 8, 25] , were the most significant characteristic independently associated with poor outcome. This association is probably due to a more aggressive tumor biology and its effect on the patient's general condition. The poor prognosis associated with number of treatment failures may be related to growth of resistant cell clones [26] , and possibly to induction of multidrug resistance genes [27] . The length of the diagnosis-to-treatment interval did not influence survival or TTF times after therapy, suggesting that the importance of the number of treatment failures was not due to longer duration of disease. It is clear that extensively pretreated patients have a very poor outcome regardless of the treatment used, and it could be argued that it is better not to include them in investigational trials. Finally, hemoglobin levels were associated with survival time; this may reflect the patient's general condition, similarly to constitutional symptoms. The prognostic factors were the same and significant for both treatment strata, suggesting that the impact of these biological determinants is independent of the relative efficacy of the treatments used. If this is proven true in confirmatory studies, the conclusions of this study could be applied to other treatments.
Transformation to a higher histologic grade of lymphoma was seen in 18% of our population. This event was associated with poor survival, as previously described [3, [28] [29] [30] . Transformation was seen in only 2 of 32 poor prognosis patients and thus did not contribute to their short survival. Our experience shows that some cases of relapsed low-grade follicular lymphomas can have an aggressive course and short survival time regardless of histologic transformation.
We present prognostic models based on easily reproducible variables that can be assessed by routine staging procedures, and we describe clearly defined groups of patients with different outcomes. If the models are confirmed in a prospective evaluation of a more uniform patient population, they could be used for patient allocation and stratification to experimental therapeutic trials. Additionally, the models could help evaluation and comparison of treatment results among diverse patient populations.
